Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 5, 2017, Pages 325-336

  Razavi, Homie ^a   Robbins, Sarah ^a   Zeuzem, Stefan ^b   Negro, Francesco ^c   Buti, Maria ^d   Duberg, Ann Sofi ^e   Roudot Thoraval, Françoise ^f   Craxi, Antonio ^g,h   Manns, Michael ^i,j   Marinho, Rui T ^k   Hunyady, Bela ^l,m   Colombo, Massimo ⁿ   Aleman, Soo ^o,p   Antonov, Krasimir ^q   Arkkila, Perttu ^r   Athanasakis, Kostas ^s   Blach, Sarah ^a   Blachier, Martin ^t   Blasco, Antonio J ^u   Calinas, Filipe ^v   Calleja, Jose L ^w   Christensen, Peer B ^x   Cramp, Matthew E ^y   Croes, Esther ^z   de Knegt, Robert J ^aa   de Ledinghen, Victor ^ab,ac   Delile, Jean Michel ^ad   Estes, Chris ^a   Falconer, Karolin ^p   Färkkilä, Martti ^r   Flisiak, Robert ^ae   Frankova, Sona ^af   Gamkrelidze, Ivane ^a   García Samaniego, Javier ^ag   Genov, Jordan ^ah   Gerstoft, Jan ^ai   Gheorghe, Liana ^aj   Goldis, Adrian ^ak   Gountas, Ilias ^a   Gregorčič, Sergeja ^al   Gschwantler, Michael ^am   Gunter, Jessie ^a   Halota, Waldemar ^an   Harcouet, Laura ^ao   Hézode, Christophe ^f   Hoffmann, Patrick ^ap   Horvath, Gabor ^aq   Hrstic, Irena ^ar   Jarčuška, Peter ^as   Jelev, Deian ^q   Jeruma, Agita ^at,au   Kåberg, Martin ^p   Kieran, Jennifer ^av   Kondili, Loreta A ^aw   Kotzev, Iskren ^ax   Krarup, Henrik ^ay   Kristian, Pavol ^as   Lagging, Martin ^az   Laleman, Wim ^ba,bb   Lázaro, Pablo ^u   Liakina, Valentina ^bc,bd   Lukšić, Boris ^be   Maimets, Matti ^bf   Makara, Mihály ^bg   Mateva, Lyudmila ^q   Maticic, Mojca ^al   Mennini, Francesco S ^bh,bi   Mitova, Rumiana ^ah   Moreno, Christophe ^bj   Mossong, Joel ^bk   Murphy, Kimberly ^a   Nde, Helen ^a   Nemecek, Vratislav ^bl   Nonkovic, Dijana ^bm   Norris, Suzanne ^av,bn   Oltman, Marian ^bo   Øvrehus, Anne L H ^x   Papatheodoridis, George ^bp   Pasini, Ken ^a   Razavi Shearer, Devin ^a   Razavi Shearer, Kathryn ^a   Reesink, Henk W ^bq   Reic, Tatjana ^br   Rozentale, Baiba ^au,bs   Ryder, Stephen D ^bt   Salupere, Riina ^bf   Sarmento Castro, Rui ^bu   Sarrazin, Christoph ^b,bv   Schmelzer, Jonathan D ^a   Schréter, Ivan ^as   Seguin Devaux, Carole ^bw   Simojoki, Kaarlo ^bx   Simonova, Marietta ^by   Smit, Peter J ^bz   Souliotis, Kyriakos ^ca,cb   Speiciene, Danute ^bc   Sperl, Jan ^af   Stärkel, Peter ^cc   Struck, Daniel ^bw   Sypsa, Vana ^cd   Thornton, Lelia ^ce   Tolmane, Ieva ^at,cf   Tomasiewicz, Krzysztof ^cg   Valantinas, Jonas ^bc   Van Damme, Pierre ^ch   van de Vijver, David ^ad   van der Meer, Adriaan J ^aa   van Santen, Daniela ^ci   Van Vlierberghe, Hans ^ch   Vandijck, Dominique ^cj,ck   Vella, Stefano ^aw   Videčnik Zorman, Jerneja ^al   Vogel, Wolfgang ^cl   Weis, Nina ^ai,cm   Hatzakis, Angelos ^cd,cn   more..

^a Center for Disease Analysis   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e Örebro University   (Sweden)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITY OF PALERMO   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j German Centre of Infection Research   (Germany)

^k UNIVERSITY OF LISBON   (Portugal)

^l Kaposi Mor Teaching Hospital   (Hungary)

^m UNIVERSITY OF PÉCS   (Hungary)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o KAROLINSKA INSTITUTE   (Sweden)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^q UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^r HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^s NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^t Public Health Expertise   (France)

^u Centro Hospitalar de Lisboa Central Hospital Santo António Capuchos ^*  (Spain)

^v Universidade de Lisboa   (Portugal)

^w HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^x ODENSE UNIVERSITY HOSPITAL   (Denmark)

^y PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^z NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^aa ERASMUS MEDICAL CENTER   (Netherlands)

^ab HAUT LÉVÊQUE HOSPITAL   (France)

^ac UNIVERSITÉ DE BORDEAUX   (France)

^ad UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ae MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^af INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^ag HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^ah UNIVERSITY HOSPITAL 'QUEEN GIOVANNA'   (Bulgaria)

^ai UNIVERSITY OF COPENHAGEN   (Denmark)

^aj FUNDENI CLINICAL INSTITUTE   (Romania)

^ak VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^al UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^am WILHELMINEN HOSPITAL   (Austria)

^an NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^ao ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^ap Directorate of Health   (Luxembourg)

^aq Hepatology Center of Buda   (Hungary)

^ar GENERAL HOSPITAL PULA   (Croatia)

^as Med Faculty of Safarik University   (Slovakia)

^at RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^au RIGA STRADINS UNIVERSITY   (Latvia)

^av ST JAMES S HOSPITAL   (Ireland)

^aw ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^ax UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^ay AALBORG UNIVERSITY HOSPITAL   (Denmark)

^az UNIVERSITY OF GOTHENBURG   (Sweden)

^ba UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^bb JESSA HOSPITAL   (Belgium)

^bc VILNIUS UNIVERSITY   (Lithuania)

^bd VILNIUS GEDIMINAS TECHNICAL UNIVERSITY   (Lithuania)

^be UNIVERSITY HOSPITAL SPLIT   (Croatia)

^bf TARTU UNIVERSITY HOSPITAL   (Estonia)

^bg Szent Laszlo Hospital   (Hungary)

^bh Centre for Economic Evaluation and Health Technology Assessment   (Italy)

^bi UNIVERSITY OF ROME TOR VERGATA   (Italy)

^bj UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^bk LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^bl NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^bm Department of Epidemiology   (Croatia)

^bn TRINITY COLLEGE DUBLIN   (Ireland)

^bo Gastroenterology and Hepatology Center   (Slovakia)

^bp UNIVERSITY OF ATHENS   (Greece)

^bq ACADEMIC MEDICAL CENTER   (Netherlands)

^br European Liver Patients' Association ELPA   (Belgium)

^bs Infectology Center of Latvia   (Latvia)

^bt NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^bu Institute of Biomedical Sciences Abel Salazar   (Portugal)

^bv ST JOSEFS HOSPITAL   (Germany)

^bw LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^bx A klinikkasaatio Finland   (Finland)

^by MILITARY MEDICAL ACADEMY   (Bulgaria)

^bz Hiv Vereniging Nederland   (Netherlands)

^ca UNIVERSITY OF PELOPONNESE   (Greece)

^cb Hellenic Centre for Mental Health and Research   (Greece)

^cc CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^cd UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^ce HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^cf UNIVERSITY OF LATVIA   (Latvia)

^cg MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^ch UNIVERSITY OF ANTWERP   (Belgium)

^ci DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^cj GHENT UNIVERSITY   (Belgium)

^ck HASSELT UNIVERSITY   (Belgium)

^cl INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^cm Mental Health Center Glostrup   (Denmark)

^cn Transmission Reduction Intervention Project Athens site   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; DELPHI STUDY; EUROPEAN UNION; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HUMAN; IMMIGRANT; IMMIGRATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MASS SCREENING; MODEL; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; VIRAL CLEARANCE; VIREMIA; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; COST OF ILLNESS; DISEASE ERADICATION; MARKOV CHAIN; MIGRATION; STATISTICS AND NUMERICAL DATA;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; COST OF ILLNESS; DISEASE ERADICATION; EMIGRATION AND IMMIGRATION; EUROPEAN UNION; HEPATITIS C; HUMANS; MARKOV CHAINS; PREVALENCE; VIREMIA; WORLD HEALTH ORGANIZATION;

EID: 85017271819     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30045-6     Document Type: Article

References (48)

1. 1 Majumdar, A, Kitson, MT, Roberts, SK, Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alilment Pharmacol Ther 46 (2016), 1276–1292.
2. 2 Hajarizadeh, B, Razavi-Shearer, D, Merat, S, Alavian, S, Malekzadeh, R, Razavi, AH, Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden. Hepat Mon, 16, 2016, e37234.
3. 3 Sharma, SA, Feld, JJ, Acute hepatitis C: management in the rapidly evolving world of HCV. Curr Gastroenterol Rep, 16, 2014, 371.
4. 4 Messina, JP, Humphreys, I, Flaxman, A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
5. 5 Au, TH, Destache, CJ, Vivekanandan, R, Hepatitis C therapy: looking toward interferon-sparing regimens. J Am Pharm Assoc 55 (2015), e72–e84.
6. 6 Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388 (2016), 1081–1088.
7. 7 Razavi, H, Elkhoury, AC, Elbasha, E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57 (2013), 2164–2170.
8. 8 Deuffic-Burban, S, Deltenre, P, Buti, M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology, 143, 2012, 974 85.e14.
9. 9 Ribes, J, Cleries, R, Esteban, L, Moreno, V, Bosch, FX, The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 49 (2008), 233–242.
10. 10 Bosetti, C, Levi, F, Boffetta, P, Lucchini, F, Negri, E, La Vecchia, C, Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 48 (2008), 137–145.
11. 11 Dillon, JF, Lazarus, JV, Razavi, HA, Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatology, 1, 2016, 2.
12. 12 Martin, NK, Vickerman, P, Hickman, M, Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 274 (2011), 58–66.
13. 13 Friedland, G, Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 55:suppl 1 (2010), S37–S42.
14. 14 Nelson, PK, Mathers, BM, Cowie, B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
15. 15 Price, H, Gilson, R, Mercey, D, et al. Hepatitis C in men who have sex with men in London—a community survey. HIV Med 14 (2013), 578–580.
16. 16 Vanhommerig, JW, Lambers, FA, Schinkel, J, et al. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis, 2, 2015, ofv115.
17. 17 van der Helm, JJ, Prins, M, del Amo, J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 25 (2011), 1083–1091.
18. 18 WHO. Draft global health sector strategy on viral hepatitis 2016–2021—the first of it its kind. http://www.who.int/hepatitis/strategy2016-2021/Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf, Nov 13, 2015 (accessed Oct 9, 2016).
19. 19 WHO. Combating hepatitis B and C to reach elimination by 2030, 2016, World Health Organization, Geneva.
20. 20 Hickman, M, De Angelis, D, Vickerman, P, Hutchinson, S, Martin, NK, Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 28 (2015), 576–582.
21. 21 Wedemeyer, H, Dore, GJ, Ward, JW, Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat 22:suppl 1 (2015), 1–5.
22. 22 Razavi, H, Waked, I, Sarrazin, C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21:suppl 1 (2014), 34–59.
23. 23 Esteban, JI, Sauleda, S, Quer, J, The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48 (2008), 148–162.
24. 24 Hope, VD, Eramova, I, Capurro, D, Donoghoe, MC, Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 142 (2014), 270–286.
25. 25 Razavi, H, Estes, C, Pasini, K, Gower, E, Hindman, S, HCV treatment rate in select European countries in 2004–2010. J Hepatol 58 (2013), S22–S23.
26. 26 Eurostat. Asylum and first time asylum applicants by citizenship, age and sex. Annual aggregated data (rounded). http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=migr_asyappctza&lang=en (accessed Jan 28, 2015).
27. 27 Federal Ministry of the Interior. Announcement of the latest refugee figures. http://www.bmi.bund.de/SharedDocs/Pressemitteilungen/EN/2016/announcement-latest-refugee-figures.html, Sept 30, 2016 (accessed Dec 12, 2016).
28. 28 Greenaway, C, Ma, AT, Kloda, LA, et al. The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta-analysis. PLoS One, 10, 2015, e0141715.
29. 29 The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2016), 161–176.
30. 30 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. http://www.easl.eu/medias/cpg/HCV2016/Summary.pdf, September, 2016 (accessed Oct 14, 2016).
31. 31 Malcolm, DG, Roseboom, JH, Clark, CE, Fazar, W, Application of a technique for research and development program evaluation. Operations Res 7 (1959), 646–669.
32. 32 Bedossa, P, Poynard, T, An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996), 289–293.
33. 33 Edlin, BR, Eckhardt, BJ, Shu, MA, Holmberg, SD, Swan, T, Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 62 (2015), 1353–1363.
34. 34 Denniston, MM, Klevens, RM, McQuillan, GM, Jiles, RB, Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology 55 (2012), 1652–1661.
35. 35 Polaris Observatory. http://polarisobservatory.org/polaris/hepC.htm (accessed Jan 23, 2017).
36. 36 Marcellin, P, Gane, E, Buti, M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
37. 37 Scott, N, McBryde, ES, Thompson, A, Doyle, JS, Hellard, ME, Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut, 2016, 10.1136/gutjnl-2016-311504 published online April 12.
38. 38 Cousien, A, Tran, VC, Deuffic-Burban, S, Jauffret-Roustide, M, Dhersin, JS, Yazdanpanah, Y, Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 63 (2016), 1090–1101.
39. 39 Martin, NK, Foster, GR, Vilar, J, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat 22 (2015), 399–408.
40. 40 Martin, NK, Vickerman, P, Grebely, J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
41. 41 Hellard, ME, Jenkinson, R, Higgs, P, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 196 (2012), 638–641.
42. 42 Gimeno-Ballester, V, Buti, M, San Miguel, R, Riveiro, M, Esteban, R, Interferon-free therapies for patients with chronic hepatitis c genotype 3 infection: a systematic review. J Viral Hepat, 2016, 10.1111/jvh.12660 published online Dec 7.
43. 43 Alonso, S, Riveiro-Barciela, M, Fernandez, I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat, 2016, 10.1111/jvh.12648 published online Dec 9.
44. 44 Ansaldi, F, Bruzzone, B, Salmaso, S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 76 (2005), 327–332.
45. 45 Marcellusi, A, Viti, R, Capone, A, Mennini, FS, Direct and indirect cost of HCV-related diseases in Italy: an incidence-based probabilistic approach. Value Health, 17, 2014, A671.
46. 46 Cozzolongo, R, Osella, AR, Elba, S, et al. Epidemiology of HCV and HBV in the general population: a survey in a southern Italian town. J Hepatol, 50, 2009, S150.
47. 47 Sharma, S, Carballo, M, Feld, JJ, Janssen, HL, Immigration and viral hepatitis. J Hepatol 63 (2015), 515–522.
48. 48 Conseil national du sida et des hépatites virales. Creating the conditions for universal access to new hepatitis C treatments. http://cns.sante.fr/press-release/creating-the-conditions-for-universal-access-to-new-hepatitis-c-treatments/, May 20, 2016 (accessed Oct 11, 2016).